Literature DB >> 19374149

Assessing the additional disease burden of polyps in chronic rhinosinusitis.

Neil Bhattacharyya1.   

Abstract

OBJECTIVES: This study was undertaken to determine the differential disease burden between chronic rhinosinusitis (CRS) cases with and without nasal polyposis (NP).
METHODS: A consecutive series of adult patients who met clinical and radiographic criteria for CRS was assessed with the Rhinosinusitis Symptom Inventory, nasal endoscopy, and computed tomography. Three clinical groups were examined: 1) CRS without NP, 2) CRS with primary NP (no prior surgery), and 3) CRS with recurrent NP (prior surgery). The groups were compared with respect to symptom presentation, medical resource utilization, and medication costs.
RESULTS: Two hundred eighty-six CRS cases without NP, 131 CRS cases with primary NP, and 45 CRS cases with recurrent NP were studied; their mean Lund scores were 8.8, 13.2, and 16.3, respectively (p < 0.001). Statistically significant differences in severity for nasal (p = 0.002), facial (p = 0.025), oropharyngeal (p = 0.017), and systemic symptoms (p = 0.042) between groups were noted, whereas total symptoms did not differ between groups (p = 0.339). Medication use and physician visits were similar between groups (p = 0.335 and p = 0.951, respectively). The aggregate yearly medication costs were significantly greater for the recurrent polyp group ($866) than for either the non-polyp group ($570; p = 0.013) or the primary polyp group ($565; p = 0.020).
CONCLUSIONS: Patients with non-polyp CRS and those with primary polyp CRS present with different symptom phenotypes, but exhibit similar total symptom burdens and medical resource consumption. The presence of polyps does not necessarily confer a dramatic additional disease burden in CRS.

Entities:  

Mesh:

Year:  2009        PMID: 19374149     DOI: 10.1177/000348940911800305

Source DB:  PubMed          Journal:  Ann Otol Rhinol Laryngol        ISSN: 0003-4894            Impact factor:   1.547


  13 in total

1.  Longitudinal Evaluation of Chronic Rhinosinusitis Symptoms in a Population-Based Sample.

Authors:  Agnes S Sundaresan; Annemarie G Hirsch; Amanda J Young; Jonathan Pollak; Bruce K Tan; Robert P Schleimer; Robert C Kern; Thomas L Kennedy; J Scott Greene; Walter F Stewart; Karen Bandeen-Roche; Brian S Schwartz
Journal:  J Allergy Clin Immunol Pract       Date:  2017-11-10

2.  Nasal and sinus symptoms and chronic rhinosinusitis in a population-based sample.

Authors:  A G Hirsch; W F Stewart; A S Sundaresan; A J Young; T L Kennedy; J Scott Greene; W Feng; B K Tan; R P Schleimer; R C Kern; A Lidder; B S Schwartz
Journal:  Allergy       Date:  2016-09-19       Impact factor: 13.146

Review 3.  Chronic rhinosinusitis, race, and ethnicity.

Authors:  Zachary M Soler; Jess C Mace; Jamie R Litvack; Timothy L Smith
Journal:  Am J Rhinol Allergy       Date:  2012 Mar-Apr       Impact factor: 2.467

4.  IL-5Rα marks nasal polyp IgG4- and IgE-expressing cells in aspirin-exacerbated respiratory disease.

Authors:  Kathleen M Buchheit; Daniel F Dwyer; Jose Ordovas-Montanes; Howard R Katz; Erin Lewis; Marko Vukovic; Juying Lai; Lora G Bankova; Neil Bhattacharyya; Alex K Shalek; Nora A Barrett; Joshua A Boyce; Tanya M Laidlaw
Journal:  J Allergy Clin Immunol       Date:  2020-03-19       Impact factor: 10.793

5.  Antimicrobial therapy in chronic rhinosinusitis.

Authors:  Neil Bhattacharyya
Journal:  Curr Allergy Asthma Rep       Date:  2009-05       Impact factor: 4.806

Review 6.  Local immunoglobulin production in nasal tissues: A key to pathogenesis in chronic rhinosinusitis with nasal polyps and aspirin-exacerbated respiratory disease.

Authors:  Kathleen M Buchheit; Kathryn E Hulse
Journal:  Ann Allergy Asthma Immunol       Date:  2020-10-13       Impact factor: 6.347

Review 7.  Clinical Research Needs for the Management of Chronic Rhinosinusitis with Nasal Polyps in the New Era of Biologics: A National Institute of Allergy and Infectious Diseases Workshop.

Authors:  Robert Naclerio; Fuad Baroody; Claus Bachert; Benjamin Bleier; Larry Borish; Erica Brittain; Geoffrey Chupp; Anat Fisher; Wytske Fokkens; Philippe Gevaert; David Kennedy; Jean Kim; Tanya M Laidlaw; Jake J Lee; Jay F Piccirillo; Jayant M Pinto; Lauren T Roland; Robert P Schleimer; Rodney J Schlosser; Julie M Schwaninger; Timothy L Smith; Bruce K Tan; Ming Tan; Elina Toskala; Sally Wenzel; Alkis Togias
Journal:  J Allergy Clin Immunol Pract       Date:  2020-03-04

8.  Mepolizumab targets multiple immune cells in aspirin-exacerbated respiratory disease.

Authors:  Kathleen M Buchheit; Erin Lewis; Deborah Gakpo; Jonathan Hacker; Aaqib Sohail; Faith Taliaferro; Evans Berreondo Giron; Chelsea Asare; Marko Vukovic; Jillian C Bensko; Daniel F Dwyer; Alex K Shalek; Jose Ordovas-Montanes; Tanya M Laidlaw
Journal:  J Allergy Clin Immunol       Date:  2021-06-16       Impact factor: 14.290

9.  Defining the Allergic Endotype of Chronic Rhinosinusitis by Structured Histopathology and Clinical Variables.

Authors:  Hannah J Brown; Bobby A Tajudeen; Hannah N Kuhar; Paolo Gattuso; Pete S Batra; Mahboobeh Mahdavinia
Journal:  J Allergy Clin Immunol Pract       Date:  2021-06-24

10.  Comparison of sinonasal symptoms in patients with nasal septal deviation and patients with chronic rhinosinusitis.

Authors:  Mohammad Naeimi; Maria Garkaz; Mohammad Reza Naeimi
Journal:  Iran J Otorhinolaryngol       Date:  2013
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.